Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Leukocytes01:27

Disorders of Leukocytes

924
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
924
Lampbrush Chromosomes01:51

Lampbrush Chromosomes

7.9K
In 1882, Flemming observed lampbrush chromosomes (LBC) in salamander eggs. Later in 1892, Rückert observed LBCs in shark egg cells and coined the term "lampbrush chromosomes" because they looked like brushes used to clean kerosene lamps.
LBCs are made up of two pairs of conjugating homologous chromatids. Each chromatid consists of alternatively positioned regions of condensed-inactive chromatin and loosely placed-active side loops, which can be contracted and extended. The loops...
7.9K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

972
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
972

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026
Same author

Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.

Haematologica·2026
Same author

Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

Blood cancer journal·2026
Same author

Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Haematologica·2026
Same author

Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoring.

Leukemia & lymphoma·2026

関連する実験動画

Updated: Jun 18, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.1K

慢性リンパ球白血病

Nitin Jain1, William G Wierda1, Susan O'Brien2

  • 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Lancet (London, England)
|July 28, 2024
PubMed
まとめ
この要約は機械生成です。

標的治療は慢性リンパ球性白血病 (CLL) の治療における化学免疫療法を上回り,生存率を向上させました. BTKやBCL2阻害剤のような新しい薬剤は,現在,初期および再発性CLL治療の標準です.

さらに関連する動画

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.5K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.4K

関連する実験動画

Last Updated: Jun 18, 2025

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.1K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.5K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.4K

科学分野:

  • 血液学
  • 腫瘍学
  • 薬理学について

背景:

  • 慢性リンパ球性白血病 (CLL) の治療は著しく進歩しました.
  • 化学免疫療法は改善された結果のために標的治療法に置き換えられています.

研究 の 目的:

  • CLL疾患の生物学と標的治療の進歩をレビューする.
  • 第一線および再発性CLL治療における標的薬の現在の役割について議論する.

主な方法:

  • ランダム化臨床試験と進行中のフェーズ3試験のレビュー
  • CLLの既定および新興の治療戦略の分析

主要な成果:

  • ブルートンチロシンキナーゼ (BTK) 阻害剤,BCL2阻害剤,CD20単体抗体を含む標的治療は,化学免疫療法と比較して,より優れた進行性および全生存率を示しています.
  • これらの標的薬は,第一線および再発/耐性CLLの両方に標準です.

結論:

  • CLLの治療は標的型療法に 移行しています
  • 進行中の臨床試験では,非共性BTK阻害剤やCART細胞療法などの新薬がCLLの管理をさらに精進させる可能性がある.